NanoString stock price target raised to $20 from $17 at J.P. Morgan
NanoString stock price target raised to $20 from $17 at J.P. Morgan
Close | Chg | Chg % | |
---|---|---|---|
$17.68 | -0.53 | -2.91% | -0.53 -2.91% |
5 Day |
|
1 Month |
|
3 Month |
|
YTD |
|
1 Year |
|
NanoString stock price target raised to $20 from $17 at J.P. Morgan
NanoString Technologies Inc. priced a follow-on offering at $12.50 a share, according to Nasdaq. The company sold 4 million shares to raise $50 million.
CORRECTED: NanoString Technologies prices follow-on offering at $12.50 a share
Robert W. Baird analyst Catherine Schulte maintained a Buy rating on NanoString Tech (NASDAQ: NSTG) ...[...]
NanoString (NSTG) Presents At Baird's Global Healthcare Conference - Slideshow
10-Q: NANOSTRING TECHNOLOGIES INC
NanoString's (NSTG) CEO Brad Gray on Q2 2018 Results - Earnings Call Transcript
NanoString (NSTG) delivered earnings and revenue surprises of -12.68% and -0.42%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies to commence equity offering
Today, Biocept (BIOC) is trading at a stock price of $10.72, which represents ~63.66% growth from yesterday’s close of $6.55.
Single-cell Analysis Market Global Industry Analysis, Size, Share, Growth By 2022
NanoString to Present at the Morgan Stanley Global Healthcare Conference
Precision Medicine Market will see 10.5% CAGR to beat $96 Billion by 2024
NanoString Launches Priority Site Program for New GeoMx Digital Spatial Profiler
Single cell Analysis Market Key Manufactures and Opportunity Analysis By 2022
NanoString to Present at the Baird 2018 Global Healthcare Conference
Single cell Analysis Market is Expected to Exceed US$ 3 Billion By 2022
Single cell Analysis Market Size worth US$ 3 Billion By 2022
NanoString Technologies Announces Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
NanoString Technologies, Inc. to Host Earnings Call
NanoString Expands Centers of Excellence Program and Initiates Early Access Launch for Digital Spatial Profiling
NanoString Technologies Announces Closing of Public Offering of 4,000,000 Shares of Common Stock
NanoString Technologies Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock
NanoString Technologies Announces Commencement of Public Offering of Common Stock
NanoString Technologies Provides Preliminary Revenue Results for Second Quarter 2018
Single-cell Analysis Market is Expected to Grow US$ 3 Billion By 2022
NanoString to Release Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 7, 2018
Single-cell Analysis Market Size is Projected to be Around US$ 3 Billion By 2022
NanoString Establishes Netherlands Cancer Institute as a Center of Excellence for Digital Spatial Profiling
NanoString Technologies, Inc. engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA. (See Full Profile)
Name | Chg % | Market Cap |
---|---|---|
Luminex Corp. | $1.3B | |
Illumina Inc. | $51.79B | |
Agilent Technologies Inc. | $21.56B | |
Bio-Rad Laboratories Inc. Cl A | $9.2B | |
Thermo Fisher Scientific Inc. | $95.23B |